Reply of the Authors: Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial.
Comments on "Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial".
Unraveling molecular heterogeneity: a systematic review of susceptibility gene profiles in ovarian, deep infiltrating, and superficial peritoneal endometriosis.
Endometriosis is a heterogeneous gynecological disease manifesting in three distinct phenotypes: superficial peritoneal endometriosis (SUP), ovarian endometrioma (OMA), and deep infiltrating endometriosis (DIE). While Genome-Wide Association Studies (GWAS) have identified …
Systemic Oxidative Stress Markers in Endometriosis: Elevated Advanced Glycation End Products and Sestrin 2 in Women with Ovarian Endometrioma.
Background/Objectives: Endometriosis is a chronic inflammatory disease characterized by ectopic endometrial tissue growth and is strongly associated with oxidative stress; however, systemic biomarkers reflecting this stress response remain limited. Advanced …
Gut Microbiota Alterations and Reproductive Tract Dysbiosis in Endometriosis: A Systematic Review.
Background and Objectives: Endometriosis is a chronic, estrogen-dependent inflammatory disease with multifactorial pathogenesis. Increasing evidence suggests that alterations in the gut and reproductive tract microbiota may contribute to disease development, …